Early Response Monitoring Following Radiation Therapy by Using [F]FDG and [C]Acetate PET in Prostate Cancer Xenograft Model with Metabolomics Corroboration

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2017 Nov 11

PMID 29125557

Citations 1

Authors

Yi-Hsiu Chung

Cheng-Kun Tsai

Chiun-Chieh Wang

Hsi-Mu Chen

Kuan-Ying Lu

Han Chiu

Yu-Chun Lin

Tzu-Chen Yen

Gigin Lin

Affiliations

Soon will be listed here.

Abstract

We aim to characterize the metabolic changes associated with early response to radiation therapy in a prostate cancer mouse model by 2-deoxy-2-[F]fluoro-d-glucose ([F]FDG) and [C]acetate ([C]ACT) positron emission tomography, with nuclear magnetic resonance (NMR) metabolomics corroboration. [F]FDG and [C]ACT PET were performed before and following irradiation (RT, 15Gy) for transgenic adenocarcinoma of mouse prostate xenografts. The underlying metabolomics alterations of tumor tissues were analyzed by using ex vivo NMR. The [F]FDG total lesion glucose (TLG) of the tumor significant increased in the RT group at Days 1 and 3 post-irradiation, compared with the non-RT group (p < 0.05). The [C]ACT maximum standard uptake value (SUVmax) in RT (0.83 ± 0.02) and non-RT groups (0.85 ± 0.07) were not significantly different (p > 0.05). The ex vivo NMR analysis showed a 1.70-fold increase in glucose and a 1.2-fold increase in acetate in the RT group at Day 3 post-irradiation (p < 0.05). Concordantly, the expressions of cytoplasmic acetyl-CoA synthetase in the irradiated tumors was overexpressed at Day 3 post-irradiation (p < 0.05). Therefore, TLG of [F]FDG in vivo PET images can map early treatment response following irradiation and be a promising prognostic indicator in a longitudinal preclinical study. The underlying metabolic alterations was not reflected by the [C]ACT PET.

Citing Articles

Analysis of volatile organic compounds in exhaled breath after radiotherapy.

Ge D, Zou X, Chu Y, Zhou J, Xu W, Liu Y J Zhejiang Univ Sci B. 2022; 23(2):153-157.

PMID: 35187888 PMC: 8861557. DOI: 10.1631/jzus.B2100447.

References

Buzdar S, Afzal M, Nazir A, Gadhi M . Accuracy requirements in radiotherapy treatment planning. J Coll Physicians Surg Pak. 2013; 23(6):418-23. DOI: 06.2013/JCPSP.418423. View

Hentschel M, Appold S, Schreiber A, Abolmaali N, Abramyuk A, Dorr W . Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2011; 38(7):1203-11. DOI: 10.1007/s00259-011-1759-3. View

Oyama N, Kim J, Jones L, Mercer N, Engelbach J, Sharp T . MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nucl Med Biol. 2002; 29(8):783-90. DOI: 10.1016/s0969-8051(02)00346-3. View

Castaldi P, Rufini V, Bussu F, Micciche F, Dinapoli N, Autorino R . Can "early" and "late"18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy?. Radiother Oncol. 2012; 103(1):63-8. DOI: 10.1016/j.radonc.2012.03.001. View

Larson S, Erdi Y, Akhurst T, Mazumdar M, Macapinlac H, Finn R . Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging. 2003; 2(3):159-171. DOI: 10.1016/s1095-0397(99)00016-3. View

Dewey W, Ling C, Meyn R . Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys. 1995; 33(4):781-96. DOI: 10.1016/0360-3016(95)00214-8. View

MONAKHOV N, Neistadt E, Shavlovskil M, Shvartsman A, NEIFAKH S . Physicochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues. J Natl Cancer Inst. 1978; 61(1):27-34. DOI: 10.1093/jnci/61.1.27. View

van Dijk L, Boerman O, Franssen G, Lok J, Kaanders J, Bussink J . Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model. J Nucl Med. 2014; 55(10):1665-70. DOI: 10.2967/jnumed.114.141762. View

Chung Y, Hsu P, Huang C, Hsieh W, Huang F, Chang W . Evaluation of prognostic integrin α2β1 PET tracer and concurrent targeting delivery using focused ultrasound for brain glioma detection. Mol Pharm. 2014; 11(11):3904-14. DOI: 10.1021/mp500296n. View

10.

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V . Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 366(9503):2087-106. DOI: 10.1016/S0140-6736(05)67887-7. View

11.

Beckonert O, Keun H, Ebbels T, Bundy J, Holmes E, Lindon J . Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc. 2007; 2(11):2692-703. DOI: 10.1038/nprot.2007.376. View

12.

Jeraj R, Bradshaw T, Simoncic U . Molecular Imaging to Plan Radiotherapy and Evaluate Its Efficacy. J Nucl Med. 2015; 56(11):1752-65. DOI: 10.2967/jnumed.114.141424. View

13.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

14.

van Dijk L, Boerman O, Franssen G, Kaanders J, Bussink J . 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model. J Nucl Med. 2015; 56(2):287-92. DOI: 10.2967/jnumed.114.148296. View

15.

Chang J, Zhang X, Wang X, Kang Y, Riley B, Bilton S . Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006; 65(4):1087-96. DOI: 10.1016/j.ijrobp.2006.01.052. View

16.

Min M, Lin P, Lee M, Shon I, Lin M, Forstner D . Prognostic role of metabolic parameters of (18)F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2015; 42(13):1984-94. PMC: 4623084. DOI: 10.1007/s00259-015-3104-8. View

17.

Chen A, Chu W, Gu Y, Cunningham C, Cunnhingham C . Probing early tumor response to radiation therapy using hyperpolarized [1-¹³C]pyruvate in MDA-MB-231 xenografts. PLoS One. 2013; 8(2):e56551. PMC: 3570408. DOI: 10.1371/journal.pone.0056551. View

18.

Cascini G, Avallone A, Delrio P, Guida C, Tatangelo F, Marone P . 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med. 2006; 47(8):1241-8. View

19.

Castaldi P, Leccisotti L, Bussu F, Micciche F, Rufini V . Role of (18)F-FDG PET-CT in head and neck squamous cell carcinoma. Acta Otorhinolaryngol Ital. 2013; 33(1):1-8. PMC: 3631810. View

20.

Lee J, Kim S, Kil I, Park J . Regulation of ionizing radiation-induced apoptosis by mitochondrial NADP+-dependent isocitrate dehydrogenase. J Biol Chem. 2007; 282(18):13385-94. DOI: 10.1074/jbc.M700303200. View